CASEY SHOWS: Open Payments
NPI 1164941548 · JACKSON, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$463 in 23 payments from 9 companies in 2025. Trend: 2023 $0 · 2024 $306 · 2025 $463
Food & beverage: $463
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 7 | $141 |
| Electromed, Inc. | 8 | $136 |
| Ambu Inc. | 1 | $34 |
| ABBVIE INC. | 1 | $33 |
| Merck Sharp & Dohme LLC | 2 | $30 |
| GENZYME CORPORATION | 1 | $26 |
| Mallinckrodt Hospital Products Inc. | 1 | $26 |
| AstraZeneca Pharmaceuticals LP | 1 | $19 |
| 3B Medical, Inc. | 1 | $17 |
Products named: SMARTVEST, TRELEGY ELLIPTA, TEFLARO, ZERBAXA, DUPIXENT, ACTHAR, NUCALA, BREZTRI.
Industry payments across MS — which companies pay providers there.
